Expedited approvals for new cancer drugs have led to massive revenue increases for pharmaceutical companies. However, a large number of these treatments aren’t proven to extend the lives of patients very long, if at all. Meanwhile, drugs that do work are sometimes prescribed in far higher volumes than necessary, increasing Big Pharma’s bottom line.
0:00 Hope vs. Profits
1:04 Compassionate Care
5:08 Speedy Approval Revelations
6:31 The Low Dose Revolution
9:52 Pushing For Sense
——–
Like this video? Subscribe: http://www.youtube.com/Bloomberg?sub_confirmation=1
Get unlimited access to Bloomberg.com for $1.99/month for the first 3 months: https://www.bloomberg.com/subscriptions?in_source=YoutubeOriginals
Bloomberg Originals offers bold takes for curious minds on today’s biggest topics. Hosted by experts covering stories you haven’t seen and viewpoints you haven’t heard, you’ll discover cinematic, data-led shows that investigate the intersection of business and culture. Exploring every angle of climate change, technology, finance, sports and beyond, Bloomberg Originals is business as you’ve never seen it.
Subscribe for business news, but not as you’ve known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.
Visit our partner channel Bloomberg News for global news and insight in an instant.
source
